+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas



Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas



Clinical Cancer Research 6(1): 160-165



Fine-needle aspiration biopsy is a minimally invasive technique for obtaining sample material suitable not only for cytological grading but also for flow cytometry and for biochemical analyses. The prognostic value of tissue prostate-specific antigen (T-PSA) from fine-needle aspiration biopsies was compared with serum total and free prostate-specific antigen, the ratio of free:total serum prostate-specific antigen, tumor stage, cytological grade, and DNA ploidy in 179 patients with stage T2-T4 prostate cancer (CAP). The patients, who were free from bone metastases at the time of diagnosis, were treated by either orchidectomy or medical castration with GnRH analogues or high-dose parenteral depot estrogens. They were followed for at least for 71 months or until death, and the different variables were correlated to time to progression and time to death from CAP. Using Cox univariate analysis, T-PSA was shown to be the most important factor in predicting time to progression and time to death. When the patients were divided into three groups with respect to T-PSA, 56 of 60 (93%) of the patients with low T-PSA levels developed progressive disease, and 52 of 60 (87%) died of CAP. For patients with intermediate T-PSA levels, the corresponding figures were 9 of 60 (15%) and 6 of 60 (10%). None of the 59 patients with high T-PSA values developed progressive disease. Similar but less pronounced relationships were found between tumor progress and CAP-specific death on the one hand and clinical stage, cytological grade, and DNA ploidy on the other. In a Cox multivariate stepwise analysis, T-PSA was the only important factor for time to progression and death. This was also true for the subgroup of patients with stages T2 and T3 disease only. The study shows that T-PSA is superior to other hitherto routinely used markers for the prediction of outcome of hormone-treated patients with newly diagnosed CAP.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 047092574

Download citation: RISBibTeXText

PMID: 10656445


Related references

Prognostic significance of tissue PSA in endocrine treated prostate carcinomas. Scandinavian Journal of Urology & Nephrology Suppl. (200): 14-15, 1999

Prognostic significance of prostate specific antigen in endocrine treatment for stage D-2 prostate cancer. Chonnam Journal of Medical Sciences 7(2): 116-120, 1994

Prognostic significance of changes in prostate-specific antigen in patients with metastasis prostate cancer after endocrine treatment. International Urology & Nephrology 32(4): 659-663, 2001

Prognostic significance of changes in prostate-specific antigen in patients with metastasis prostate cancer after endocrine treatment. International Urology and Nephrology 32(4): 659-663, 2001

Prognostic significance of prostate-specific antigen in stage T1c prostate cancer treated by radical prostatectomy. Urology 49(6): 887-893, 1997

Outcome of patients with hormone-refractory prostate cancer: prognostic significance of prostate-specific antigen-doubling time and nadir prostate-specific antigen. Japanese Journal of Clinical Oncology 38(1): 36-42, 2008

Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy. Clinical Cancer Research 11(14): 5195-5198, 2005

Prognostic significance of changes in short-term prostate volume and serum prostate-specific antigen after androgen withdrawal in men with metastatic prostate cancer. Urologia Internationalis 70(3): 195-199, 2003

Significance of prostate-specific antigen-related factors in incidental prostate cancer treated by holmium laser enucleation of the prostate. World Journal of Urology 33(3): 329-333, 2015

Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml. Journal of Urology 158(2): 502-504, 1997

Prognostic significance of prostate-specific antigen in endocrine treatment for prostatic carcinoma. European Urology 21(Suppl. 1): 96-98, 1992

Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer. Journal of Urology 144(6): 1415-1419, 1990

Dynamics of prostate-specific antigen as prognostic factors in endocrine treatment for prostate cancer. Hinyokika Kiyo. Acta Urologica Japonica 45(1): 31-35, 1999

A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. Bju International 109(11): 1627-1635, 2012